Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medios AGMEDOF 88 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates MEDOF with a GF Score™ of 88/100 and a GF Value™ of $68.42. The stock has 2 warning signs investors should review. Among 97 Medical Distribution companies, Medios AG ranks better than 60.82% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Medios AG's Debt-to-Equity or its related term are showing as below:
MEDOF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.08 Max: 0.47
Current: 0.36
During the past 13 years, the highest Debt-to-Equity Ratio of Medios AG was 0.47. The lowest was 0.00. And the median was 0.08.
MEDOF's Debt-to-Equity is ranked better than 60.82% of 97
companies
in the Medical Distribution industry
Industry Median: 0.48
vs MEDOF: 0.36
Medios AG (OTCPK:MEDOF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Medios AG Debt-to-Equity Related Terms
Medios AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Medios AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Medios AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medios AG Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medios AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Medios AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medios AG (MEDOF) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medios AG and its competitors. According to the industry distribution chart, Medios AG ranks #38 out of 97 companies in the Medical Distribution industry, placing it in the top 39.2%.
Is Medios AG's Debt-to-Equity too high?
Medios AG's current Debt-to-Equity is 0.00. Based on the distribution chart, Medios AG ranks #38 out of 97 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Medios AG has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Medios AG's Debt-to-Equity compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Medios AG ranks #38 out of 97 companies for Debt-to-Equity. This puts Medios AG in the upper half of its industry. The industry median Debt-to-Equity is 0.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.48, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medios AG and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medios AG's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medios AG stock overvalued right now?
Medios AG (MEDOF) has a current Debt-to-Equity of 0.00. The stock's GF Value™ is $68.42, compared to a current price of $50.00 — trading 26.9% below its estimated fair value. The current Debt-to-Equity is 0.00. Medios AG's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Medios AG (MEDOF), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medios AG (MEDOF) Overvalued in 2026?
Based on GuruFocus' analysis, Medios AG stock appears to be undervalued.
The current stock price of $50.00 is trading 26.9% below its estimated GF Value™ of $68.42.
Key valuation signals for MEDOF:
Debt-to-Equity: 0.00
GF Value™: $68.42 vs. price of $50.00 (26.9% below fair value)
No single metric tells the full story. See the MEDOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medios AG is engaged as a wholesaler for pharmaceutical medicinal products. The operating segments of the company includes: Patient-Specific Therapies: This area includes the compounding of medications on behalf of pharmacies in Germany. Pharmaceautical Supply: Medios is speciality pharma supplier company in germany, producing it own production facilities, hospitals, and Pharmacies. International Business: It includes all business and activities happening in international business.
88GF Score
Get the complete analysis for MEDOF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDOF has been successfully added to your 
